@article {3320,
	title = {Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial.},
	journal = {The Lancet infectious diseases},
	volume = {12},
	year = {2012},
	month = {2012 Sep},
	pages = {671-7},
	abstract = {Several direct-acting antivirals for chronic hepatitis C virus (HCV) infection are available, but they are limited by tolerability and dosing schedules. Once-daily daclatasvir, a potent NS5A replication complex inhibitor, was generally well tolerated in phase 1 studies. We assessed daclatasvir in combination with pegylated interferon (peginterferon) and ribavirin for chronic HCV.},
	keywords = {Adult, Aged, Antiviral Agents, Double-Blind Method, Drug Therapy, Combination, Female, France, Genotype, Hepacivirus, Hepatitis C, Chronic, Humans, Imidazoles, Interferon-alpha, Male, Middle Aged, Placebos, Polyethylene Glycols, Recombinant Proteins, Ribavirin, RNA, Viral, Treatment Outcome, United States, Viral Load},
	issn = {1474-4457},
	doi = {10.1353/hpu.2012.0006},
	author = {Pol, Stanislas and Ghalib, Reem H and Rustgi, Vinod K and Martorell, Claudia and Everson, Greg T and Tatum, Harvey A and H{\'e}zode, Christophe and Lim, Joseph K and Bronowicki, Jean-Pierre and Abrams, Gary A and Br{\"a}u, Norbert and Morris, David W and Thuluvath, Paul J and Reindollar, Robert W and Yin, Philip D and Diva, Ulysses and Hindes, Robert and McPhee, Fiona and Hernandez, Dennis and Wind-Rotolo, Megan and Hughes, Eric A and Schnittman, Steven}
}
